Bristol Myers Squibb (CELG-RI) Current Assets (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Current Assets of $28.6 billion for Q2 2026, down 13.98% year-over-year from $33.2 billion in Q2 2025, and up 5.04% quarter-over-quarter from $27.2 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Current Assets (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Current Assets for 18 consecutive years, with $28.6 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Assets fell 13.98% year-over-year to $28.6 billion; the TTM figure through Jun 2026 stood at $28.6 billion (down 13.98% YoY), while the FY2025 annual figure was $29.4 billion, down 1.31% from the prior year.
- Current Assets rose to $28.6 billion in Q2 2026 per CELG-RI's latest filing, from $27.2 billion in the prior quarter.
- Across five years, Current Assets topped out at $35.6 billion in Q3 2025 and bottomed at $26.8 billion in Q3 2022.
- Historically, Current Assets has averaged $29.3 billion across 5 years, with a median of $28.6 billion in 2024.
- Annual changes were most pronounced in 2022 — Current Assets decreased 18.01% — and 2025, when it climbed 26.91%.
- Bristol Myers Squibb's Current Assets stood at $27.3 billion in 2022, then gained by 16.49% to $31.8 billion in 2023, then declined by 6.26% to $29.8 billion in 2024, then retreated by 1.31% to $29.4 billion in 2025, then fell by 2.76% to $28.6 billion in 2026.
- Business Quant data shows CELG-RI's Current Assets at $28.6 billion in Q2 2026, $27.2 billion in Q1 2026, and $29.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 28.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.58 Bn |
| Mar 31, 2026 | 27.21 Bn |
| Dec 31, 2025 | 29.39 Bn |
| Sep 30, 2025 | 35.63 Bn |
| Jun 30, 2025 | 33.22 Bn |
| Mar 31, 2025 | 30.78 Bn |
| Dec 31, 2024 | 29.78 Bn |
| Sep 30, 2024 | 28.08 Bn |
| Jun 30, 2024 | 26.89 Bn |
| Mar 31, 2024 | 28.67 Bn |
| Dec 31, 2023 | 31.77 Bn |
| Sep 30, 2023 | 27.63 Bn |
| Jun 30, 2023 | 28.07 Bn |
| Mar 31, 2023 | 27.09 Bn |
| Dec 31, 2022 | 27.27 Bn |
| Sep 30, 2022 | 26.80 Bn |
| Jun 30, 2022 | 30.19 Bn |
| Mar 31, 2022 | 30.12 Bn |
| Dec 31, 2021 | 33.26 Bn |
| Sep 30, 2021 | 31.44 Bn |